Envoy Medical, Inc. (COCH) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
N/A
—
5yr avg: N/A
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
COCH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Envoy Medical, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $14M | $13M | $27M | $23M | $102M | $99M |
| Enterprise Value | $11M | $10M | $41M | $19M | $136M | $121M |
| P/E Ratio → | -0.54 | — | — | — | — | — |
| P/S Ratio | 56.96 | 53.76 | 119.42 | 71.93 | 429.30 | 319.03 |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
COCH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 42.06 | 182.43 | 60.36 | 574.24 | 391.15 |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
COCH Profitability
Margins and return-on-capital ratios measuring operating efficiency
Envoy Medical, Inc. earns an operating margin of -9240.7%. Operating margins have compressed from -5809.8% to -9240.7% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | -262.7% | -262.7% | -229.8% | -149.7% | -110.1% | -148.1% |
| Operating Margin | -9240.7% | -9240.7% | -8558.2% | -5809.8% | -3673.4% | -2216.5% |
| Net Profit Margin | -9857.3% | -9857.3% | -9242.2% | -9469.0% | -6718.6% | -2798.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — |
| ROA | -236.4% | -236.4% | -210.0% | -552.7% | -614.8% | -330.6% |
| ROIC | — | — | — | — | — | — |
| ROCE | -4471.9% | -4471.9% | -772.4% | -3589.2% | -1363.5% | -554.1% |
COCH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $919000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -14.01 | -14.01 | -24.48 | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($919000)
COCH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.54x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.02x to 0.54x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.54 | 0.54 | 1.24 | 1.02 | 0.65 | 1.76 |
| Quick Ratio | 0.41 | 0.41 | 1.02 | 0.83 | 0.14 | 0.99 |
| Cash Ratio | 0.32 | 0.32 | 0.73 | 0.58 | 0.07 | 0.81 |
| Asset Turnover | — | 0.03 | 0.02 | 0.04 | 0.09 | 0.12 |
| Inventory Turnover | 0.57 | 0.57 | 0.43 | 0.56 | 0.38 | 0.73 |
| Days Sales Outstanding | — | 51.49 | 1326.98 | 80.85 | 63.14 | 103.61 |
COCH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Envoy Medical, Inc. returns 14.1% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | 14.1% | 14.0% | 9.1% | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 14.1% | 14.0% | 9.1% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $20M | $19M | $13M | $10M | $10M |
Peer Comparison
Compare COCH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 COCHYou | $14M | -0.5 | — | — | -262.7% | -9240.7% | — | — | — |
 LNTH | $6B | 26.7 | 14.6 | 16.7 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 WST | $23B | 47.3 | 30.8 | 49.5 | 35.9% | 20.1% | 16.9% | 17.5% | 0.6 |
 ITGR | $3B | 30.4 | 13.1 | 28.8 | 23.1% | 11.3% | 6.1% | 5.4% | 4.2 |
 AEIS | $13B | 91.7 | 51.6 | 106.3 | 37.2% | 10.9% | 11.6% | 12.2% | 2.6 |
 NOVT | $5B | 92.7 | 27.0 | 100.4 | 44.4% | 11.9% | 5.2% | 7.4% | 1.9 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 STIM | $128M | -3.1 | — | — | 48.5% | -21.1% | -134.4% | -26.6% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See COCH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs COCH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare COCH vs LNTH
Side-by-side business, growth, and profitability comparison vs Lantheus Holdings, Inc..
Start ComparisonCOCH — Frequently Asked Questions
Quick answers to the most common questions about buying COCH stock.
What is Envoy Medical, Inc.'s P/E ratio?
Envoy Medical, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Is COCH stock overvalued?
Based on historical data, Envoy Medical, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Envoy Medical, Inc.'s dividend yield?
Envoy Medical, Inc.'s current dividend yield is 14.06%.
What are Envoy Medical, Inc.'s profit margins?
Envoy Medical, Inc. has -262.7% gross margin and -9240.7% operating margin.